Valuation: AbbVie Inc.

Market Cap 506B 461B 426B 385B 725B 47,242B 753B 5,149B 2,035B 25,499B 1,897B 1,857B 80,520B P/E 2026 *
36.5x
P/E 2027 * 26.8x
Enterprise Value 569B 519B 480B 433B 815B 53,151B 847B 5,793B 2,290B 28,688B 2,134B 2,089B 90,590B EV / Sales 2026 *
8.39x
EV / Sales 2027 * 7.56x
Free-Float
95.64%
Yield 2026 *
2.41%
Yield 2027 * 2.54%
1 day-1.30%
1 week-4.24%
Current month-4.38%
1 month-0.25%
3 months+6.02%
6 months+31.91%
Current year+23.41%
1 week 279.88
Extreme 279.88
301.2
1 month 278.01
Extreme 278.01
302.93
Current year 190.75
Extreme 190.75
302.93
1 year 190.75
Extreme 190.75
302.93
3 years 137.14
Extreme 137.14
302.93
5 years 115.01
Extreme 115.01
302.93
10 years 58.6
Extreme 58.6
302.93
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 A Free

Director

59 0.0000%
9/30/26 A Free

Director

129 0.0000%
8/14/26 A Exercice

Executive/Senior Manager

98,130 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
-1.27%-4.24%+21.07%+103.87% 506B
-2.05%-4.88%+29.35%+127.18% 1,232B
-2.08%-5.87%+31.78%+78.02% 656B
-1.04%-1.80%+28.69%+68.33% 382B
-2.87%-8.59%+41.32%+30.81% 340B
-3.22%-5.20%+24.48%+50.97% 294B
-2.51%-4.49%-2.15%+31.64% 278B
-0.93%-5.57%+28.81%+66.22% 240B
-1.23%-0.48%+30.51%+119.93% 210B
-2.32%-3.84%-14.65%-62.29% 176B
Average -1.90%-2.12%+21.92%+61.47% 431B
Weighted average by Cap. -1.87%-2.58%+25.50%+81.35%

Financials

2026 *2027 *
Net sales 67.79B 61.83B 57.17B 51.59B 97.16B 6,335B 101B 690B 273B 3,419B 254B 249B 10,797B 74.02B 67.51B 62.42B 56.33B 106B 6,917B 110B 754B 298B 3,734B 278B 272B 11,789B
Net income 14.35B 13.09B 12.1B 10.92B 20.57B 1,341B 21.38B 146B 57.77B 724B 53.84B 52.71B 2,286B 19.32B 17.62B 16.29B 14.7B 27.69B 1,805B 28.78B 197B 77.77B 974B 72.47B 70.96B 3,077B
Net Debt 63.23B 57.66B 53.31B 48.11B 90.61B 5,908B 94.19B 644B 255B 3,189B 237B 232B 10,070B 54.29B 49.51B 45.78B 41.31B 77.8B 5,073B 80.87B 553B 219B 2,738B 204B 199B 8,646B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
19/11/26 $282.48 -1.24% 1,793,472
18/11/26 $286.01 -2.33% 4,842,258
17/11/26 $292.82 -0.59% 3,950,014
16/11/26 $294.55 -0.16% 5,493,798
13/11/26 $295.03 +0.20% 3,262,103
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
MarketScreener Ratings - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
286.01USD
Average target price
315.88USD
Spread / Average Target
+10.45%
  1. Stock Market
  2. Stocks
  3. ABBV Stock